Kantarjian et al53 assessed the efficacy and security of dasatinib, as compared with imatinib, for the 1st-line procedure of CML-CP. Five hundred and nineteen sufferers with newly diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of 100 mg as soon as each day (259 patients) or imatinib https://lanefzrjb.idblogmaker.com/28301650/how-much-you-need-to-expect-you-ll-pay-for-a-good-xmu-mp-1